Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 242963. Отображено 100.
05-01-2012 дата публикации

High affinity antibodies to human il-6 receptor

Номер: US20120003697A1
Автор: Ashique Rafique, Eric Smith, Gang Chen, James P. Fandl, Jeanette L. Fairhurst, Joel H. Martin, Kevin J. Pobursky, Margaret Karow, Nicholas J. Papadopoulos, Sean Stevens, Tammy T. Huang
Принадлежит: Regeneron Pharmaceuticals Inc

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K D of about 500 pM or less and blocks IL-6 activity with an IC 50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

Подробнее
Номер записи: 1
12-01-2012 дата публикации

ANTI-Aß OLIGOMER HUMANIZED ANTIBODY

Номер: US20120009179A1
Автор: Nobuyuki SUZUKI, Tsuguo Kubota
Принадлежит: Kyowa Hakko Kirin Co Ltd

An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.

Подробнее
Номер записи: 2
12-01-2012 дата публикации

Immunoglobulin variants with altered binding to protein a

Номер: US20120009182A1
Автор: Henry B. Lowman, Yik Andy Yeung
Принадлежит: Genentech Inc

Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to Staphylococcus aureus protein A, and methods of using the same are provided.

Подробнее
Номер записи: 3
12-01-2012 дата публикации

Modified Fc Molecules

Номер: US20120009205A1
Автор: Colin V. Gegg, Fei Xiong, Kenneth W. Walker, Leslie P. Miranda
Принадлежит: AMGEN INC

Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

Подробнее
Номер записи: 4
12-01-2012 дата публикации

Natriuretic activities

Номер: US20120010142A1
Автор: John C. Burnett, Jr., Timothy M. Olson
Принадлежит: Mayo Foundation for Medical Education and Research

This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.

Подробнее
Номер записи: 5
19-01-2012 дата публикации

Il-1beta binding antibodies and fragments thereof

Номер: US20120014967A1
Автор: Arnold Horwitz, Gang Chen, Linda Masat, Marina Roell, Mary Haak-Frendscho
Принадлежит: Xoma Technology Ltd USA

An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.

Подробнее
Номер записи: 6
19-01-2012 дата публикации

Anti-polyethylene glycol antibody expressing cell quantify any free polyethylene glycol and polyethylene glycol-derivatized molecules

Номер: US20120015380A1
Автор: Kuo-Hsiang Chuang, Ssu-Jung Lu, Steven R. Roffler, Tian-Lu Cheng
Принадлежит: KAOHSIUNG MEDICAL UNIVERSITY

In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH 3 O-PEG) antibodies were expressed on cell surface which can collocate with a biotinylated anti-PEG antibody (AGP4-Biotin) or biotinylated PEG (PEG-Biotin) to develop a cell-based sandwich ELISA or a cell-based competition ELISA, respectively. Both of these two methods could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.

Подробнее
Номер записи: 7
19-01-2012 дата публикации

Complement receptor 2 targeted complement modulators

Номер: US20120015871A1
Автор: Stephen Tomlinson, V. Michael Holers
Принадлежит: MUSC Foundation for Research Development, University of Colorado

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Подробнее
Номер записи: 8
19-01-2012 дата публикации

Estrogen receptors and methods of use

Номер: US20120016109A1
Автор: Zhao Yi Wang
Принадлежит: CREIGHTON UNIVERSITY

The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.

Подробнее
Номер записи: 9
26-01-2012 дата публикации

Methods and compositions for liver cancer therapy

Номер: US20120020961A1
Автор: Anne-Sophie Dume, Dominique Joubert, Frédéric HOLLANDE, Leïla Houhou
Принадлежит: Biorealites SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Institut National de la Sante et de la Recherche Medicale INSERM

The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.

Подробнее
Номер записи: 10
26-01-2012 дата публикации

Antibodies against fatty acid synthase

Номер: US20120020978A1
Автор: Patrick J. Muraca
Принадлежит: Nuclea Biotechnologies Inc

The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.

Подробнее
Номер записи: 11
26-01-2012 дата публикации

METHODS FOR TREATING IgE-MEDIATED DISORDER

Номер: US20120020979A1
Автор: Andrea Cerutti, KANG Chen
Принадлежит: CORNELL UNIVERSITY

This invention relates to methods of treating IgE mediated disorders such as allergy and asthma based on activating surface-bound IgD molecules on basophils. The invention also relates to methods of making IgD, as well as methods of screening for antimicrobial agents from IgD-activated basophils.

Подробнее
Номер записи: 12
26-01-2012 дата публикации

DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Nato3

Номер: US20120021417A1
Автор: Tomoya Nakatani, Yasuko Nakagawa, Yoshimasa Sakamoto, Yuichi Ono
Принадлежит: Eisai R&D Management Co Ltd

The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell.

Подробнее
Номер записи: 13
26-01-2012 дата публикации

Recombinant Anti-VLA4 Antibody Molecules

Номер: US20120022236A1
Автор: Frank J. Carr, Philip R. Tempest, Roy R. Lobb
Принадлежит: BIOGEN IDEC MA INC

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Подробнее
Номер записи: 14
02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1
Автор: Andrew Nixon, Anthony Williams, Daniel J. Sexton, Qi-Long Wu, Robert C. Ladner
Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее
Номер записи: 15
02-02-2012 дата публикации

Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers

Номер: US20120027779A1
Автор: Camille Grandclement, Christophe Borg, John Wijdenes
Принадлежит: Diaclone SAS, EFS Bourgogne Franche Comte, Université de Franche-Comté

The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumour cell apoptosis in the context of an anticancer treatment.

Подробнее
Номер записи: 16
02-02-2012 дата публикации

Antibody gene transfer and recombinant aav therefor

Номер: US20120027798A1
Автор: Kelly Reed Clark, Philip R. Johnson, Jr.
Принадлежит: Nationwide Childrens Hospital Inc

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

Подробнее
Номер записи: 17
02-02-2012 дата публикации

Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer

Номер: US20120027799A1
Автор: Cynthia L. Sears, Drew M. Pardoll, Franck Housseau, Shaoguang Wu
Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease).

Подробнее
Номер записи: 18
02-02-2012 дата публикации

Posterior segment drug delivery

Номер: US20120029470A1
Автор: Cary J. Reich, Douglas Sutton, Eugene de Juan, Jr., Hanson S. Gifford, Iii, K. Angela Macfarlane, Kathleen Cogan Farinas, Michael Barrett, Randolph E. Campbell, Yair Alster
Принадлежит: ForSight Vision4 Inc

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Подробнее
Номер записи: 19
09-02-2012 дата публикации

Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer

Номер: US20120034167A1
Автор: François RADVANYI, Isabelle Bernard-Pierrot, Nicolas Stransky, Yves Allory
Принадлежит: Assistance Publique Hopitaux de Paris APHP, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, INSTITUT CURIE, Universite Paris Est Creteil Paris 12

The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.

Подробнее
Номер записи: 20
09-02-2012 дата публикации

Method of Administering an Antibody

Номер: US20120034243A1
Автор: David Edward Allison, Judith A. Fox, Lee R. Brettman
Принадлежит: Genentech Inc, Millennium Pharmaceuticals Inc

Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month.

Подробнее
Номер записи: 21
09-02-2012 дата публикации

Methods of treating secondary bone tumors with antibodies against pdgfr alpha

Номер: US20120034244A1
Автор: Alessandro FATATIS, Nathan Graeme DOLLOFF, Nick LOIZOS
Принадлежит: ImClone LLC, Philadelphia Health and Education Corp

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Подробнее
Номер записи: 22
09-02-2012 дата публикации

Cell lines producing blocking antibodies to human RANKL

Номер: US20120034690A1
Автор: Dirk M. Anderson
Принадлежит: Immunex Corp

Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.

Подробнее
Номер записи: 23
09-02-2012 дата публикации

Compositions and methods for the treatment of immune related diseases

Номер: US20120035073A1
Автор: Brisdell Hunte, Hilary Clark, Janet K. Jackman, Jill R. Schoenfeld, P. Mickey Williams, Sarah C. Bodary-Winter, Thomas D. Wu, William I. Wood
Принадлежит: Individual

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Подробнее
Номер записи: 24
16-02-2012 дата публикации

Methods of treating pain

Номер: US20120039866A1
Автор: Daniela Salvemini
Принадлежит: St Louis University

The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.

Подробнее
Номер записи: 25
16-02-2012 дата публикации

Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof

Номер: US20120039874A1
Автор: Katsunari Tezuka, Nobuaki Hori, Takashi Tsuji
Принадлежит: Japan Tobacco Inc

Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.

Подробнее
Номер записи: 26
16-02-2012 дата публикации

Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-b-amyloid antibody

Номер: US20120039897A1
Автор: Marilena Manea, Michael Bacher, Michael Przybylski, Raluca Stefanescu, Richard Dodel
Принадлежит: Philipps Universitaet Marburg

Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Подробнее
Номер записи: 27
16-02-2012 дата публикации

Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof

Номер: US20120039899A1
Автор: Andres G. Grandea, III, Christina L. Boozer, Ole Olsen
Принадлежит: Theraclone Sciences Inc

The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.

Подробнее
Номер записи: 28
16-02-2012 дата публикации

Glioblastoma multiforme-reactive antibodies and methods of use thereof

Номер: US20120039915A1
Автор: Bin Liu, James D. Marks, Scott Bidlingmaier, Xiaodong Zhu
Принадлежит: UNIVERSITY OF CALIFORNIA

The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.

Подробнее
Номер записи: 29
16-02-2012 дата публикации

Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells

Номер: US20120039916A1
Автор: Anne-Laure Flamar, Gérard ZURAWSKI, Jacques F. Banchereau
Принадлежит: BAYLOR RESEARCH INSTITUTE

Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation.

Подробнее
Номер записи: 30
16-02-2012 дата публикации

RBM3 in Testicular Cancer Diagnostics and Prognostics

Номер: US20120040338A1
Автор: Jakob Eberhard, Karin Jirstrom
Принадлежит: Atlas Antibodies AB

The present disclosure provides a method for determining whether a mammalian subject belongs to a first or a second group, wherein subjects of the first group have a higher risk of having a testicular disorder than subjects of the second group, comprising the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA in at least part of an earlier obtained sample comprising biological material from a testicle of said subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group. Further, a prognostic method for testicular cancer is provided, as well as means and uses with prognostic and diagnostic applications.

Подробнее
Номер записи: 31
16-02-2012 дата публикации

Method of detecting progression of a neurodementing disease

Номер: US20120040382A1
Автор: Marilena Manea, Michael Bacher, Michael Przybylski, Raluca Stefanescu, Richard Dodel
Принадлежит: Philipps Universitaet Marburg

Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

Подробнее
Номер записи: 32
16-02-2012 дата публикации

Antibody fusion-mediated plant resistance against Oomycota

Номер: US20120042416A1
Автор: Dieter Peschen, Rainer Fischer, Stefan Schillberg, Sylvia Schleker
Принадлежит: Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV

The present invention relates to fusion proteins comprising anti-Oomycotic proteins or peptides linked to an antibody or fragment thereof specifically recognising an epitope of an Oomycota. The invention is also directed to polynucleotides coding for the fusion proteins. The embodiments of the present invention are particularly useful for the protection of plants against Oomycota. The invention therefore comprises transgenic plants expressing the fusion proteins of the present invention.

Подробнее
Номер записи: 33
23-02-2012 дата публикации

Engineered anti-il-13 antibodies, compositions, methods and uses

Номер: US20120045438A1
Автор: Alexey V. Teplyakov, Ellen Chi, Gopalan Raghunathan, Hong Mimi Zhou, Jill Giles-Komar, Jill M. Carton, Johan Fransson, Juan C. Almagro, Karyn T. O'neil, Linus Hyun, Ronald V. Swanson, Shanrong Zhao, Wendy Cordier, Yiqing Feng
Принадлежит: Centocor Ortho Biotech Inc

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Подробнее
Номер записи: 34
23-02-2012 дата публикации

Human monoclonal antibodies to ctla-4

Номер: US20120045442A1
Автор: C. Geoffrey Davis, Douglas Charles Hanson, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Jose Ramon Corvalan, Mark Joseph Neveu, Steven Christopher Gilman
Принадлежит: Abgenix Inc, PFIZER INC

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

Подробнее
Номер записи: 35
23-02-2012 дата публикации

Stabilized anti-respiratory syncytial virus (rsv) antibody formulations

Номер: US20120045456A1
Автор: Christian B. Allan, Cynthia N. Oliver, Stephen T. Chang
Принадлежит: MEDIMMUNE LLC

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

Подробнее
Номер записи: 36
23-02-2012 дата публикации

TREATMENT OF CELIAC DISEASE WITH IgA

Номер: US20120045517A1
Автор: Mark Andrew Kroenke, Michael Richard Simon
Принадлежит: Individual

A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

Подробнее
Номер записи: 37
23-02-2012 дата публикации

ANTI-lgSF4 ANTIBODY AND UTILIZATION OF THE SAME

Номер: US20120046451A1
Автор: Akihiko Takasaki, Atsushi Sugioka, Chiho Muramatsu, Gene Kurosawa, Kazuhiro Morishita, Kazuhiro Suzuki, Kazuki Matsuda, Keiko Ogawa, Mariko Sumitomo, Masachika Azuma, Miwa Morita, Nobuhiro Hayashi, Nobuhiro Takahashi, Sari Fujiyama, Susumu Tsutsumi, Yasushi Akahori, Yoshikazu Kurosawa, Yoshinori Ukai, Yoshitaka Iba
Принадлежит: Institute for Antibodies Co Ltd

It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Подробнее
Номер записи: 38
01-03-2012 дата публикации

Peripheral blood sparc binding antibodies and uses thereof

Номер: US20120052007A1
Автор: Neil Desai, Vuong Trieu, Xiping Liu
Принадлежит: Abraxis Bioscience Llc

The invention provides SPARC binding antibodies that have high affinity to SPARC, particularly plasma SPARC, and methods of using such antibodies in treating conditions including cancer.

Подробнее
Номер записи: 39
01-03-2012 дата публикации

Methods of diagnosing cervical cancer

Номер: US20120052484A1
Автор: Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer, Michael P. Belmares, Peter S. Lu
Принадлежит: Individual

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

Подробнее
Номер записи: 40
01-03-2012 дата публикации

Anti-vegf-c antibodies and methods using same

Номер: US20120052566A9
Автор: Anil D. Bagri, Chingwei V. Lee, Germaine Fuh
Принадлежит: F Hoffmann La Roche AG

The invention provides VEGF-C antagonists, such as anti-VEGF-C antibodies, and their use in the prevention and treatment of tumor progression.

Подробнее
Номер записи: 41
08-03-2012 дата публикации

Anti- integrin antibodies, compositions, methods and uses

Номер: US20120058128A1
Автор: Jill Giles-Komar, Linda Snyder, Marian T. Nakada, Mohit Trikha
Принадлежит: Janssen Biotech Inc

The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Подробнее
Номер записи: 42
08-03-2012 дата публикации

Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved

Номер: US20120058572A1
Автор: Naruto Katsuragi, Ryuichi Morishita, Yoshiaki Taniyama
Принадлежит: Daiichi Sankyo Co Ltd, Osaka University NUC

The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.

Подробнее
Номер записи: 43
08-03-2012 дата публикации

Methods of Treating Neurological Disorders

Номер: US20120058949A1
Автор: Alon Friedman, Daniela Kaufer, Luisa Cacheaux
Принадлежит: Alon Friedman, Daniela Kaufer, Luisa Cacheaux

The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.

Подробнее
Номер записи: 44
15-03-2012 дата публикации

Method for Treating Psoriatic Arthritis by Administering an Anti-IL-12 Antibody

Номер: US20120063998A1
Автор: Bemard Scallon, David M. Knight, David Peritt, David Shealy, Jill Giles-Komar
Принадлежит: Individual

Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis.

Подробнее
Номер записи: 45
15-03-2012 дата публикации

Psca: prostate stem cell antigen and uses thereof

Номер: US20120063999A1
Автор: Aya Jakobovitz, Douglas C. Saffran, Owen N. Witte, Robert E. Reiter
Принадлежит: Agensys Inc, UNIVERSITY OF CALIFORNIA

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Подробнее
Номер записи: 46
15-03-2012 дата публикации

Monoclonal Antibodies to Hepatocyte Growth Factor

Номер: US20120064066A1
Автор: Kyung Jin Kim, Yi-Chi Su
Принадлежит: Galaxy Biotech LLC

The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Подробнее
Номер записи: 47
15-03-2012 дата публикации

Il-17 homologous polypeptides and therapeutic uses thereof

Номер: US20120064073A1
Автор: Audrey Goddard, Austin L. Gurney, Colin K. Watanabe, Daniel G. Yansura, Daniel Tumas, Dorothy French, Ellen Fllvaroff, Hanzhong Li, J. Christopher Grimaldi, James Pan, Jian Chen, Kenneth J. Hillan, Melissa A. Starovasnik, Menno Van Lookeren, P. Mickey Williams, Paul J. Godowski, Richard Vandlen, Sarah G. Hymowitz, Sherman Fong, William I. Wood
Принадлежит: Individual

The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Подробнее
Номер записи: 48
15-03-2012 дата публикации

Aminoacyl trna synthetases for modulating hematopoiesis

Номер: US20120064082A1
Автор: Alain P. Vasserot, Jeffry Dean Watkins, Leslie Ann Greene, Rajesh Belani, Ryan Andrew Adams
Принадлежит: aTyr Pharma Inc

Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.

Подробнее
Номер записи: 49
15-03-2012 дата публикации

Therapeutic use of anti-cs1 antibodies

Номер: US20120064083A1
Автор: Gao Liu, J. Yun Tso, Marna Williams, Nicholas F. Landolfi
Принадлежит: Abbott Biotherapeutics Corp

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

Подробнее
Номер записи: 50
15-03-2012 дата публикации

Novel Target for Regulating Multiple Sclerosis

Номер: US20120064092A1
Автор: Brian A. Zabel, Eugene C. Butcher, Kareem Graham
Принадлежит: Leland Stanford Junior University, US Department of Veterans Affairs VA

Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.

Подробнее
Номер записи: 51
15-03-2012 дата публикации

Enhanced Binding of Pro-Inflammatory Cytokines by Polysaccharide-Antibody Conjugates

Номер: US20120064097A1
Автор: Liang Tso Sun, Newell R. Washburn
Принадлежит: WASHBURN THERAPEUTICS Inc

We provide monoclonal antibodies against interleukin-1β and tumor necrosis factor-α that remain biologically active in vitro when conjugated to high molecular weight polysaccharides. We report enhanced binding of these cytokines when their monoclonal antibodies are conjugated to alginate compared to non-conjugated monoclonal antibodies. In cell assays, polysaccharide-antibody constructs of the invention inhibited cytokine signaling to comparable levels as that of unmodified antibodies. Conjugation of cytokine-neutralizing antibodies to high molecular weight polymers enhances the affinities cytokine-binding moieties used as anti-inflammatory therapeutics.

Подробнее
Номер записи: 52
15-03-2012 дата публикации

assay for detecting vitamin d and antibodies therefor

Номер: US20120064533A1
Автор: David Pritchard, Lars Orning, Margaret Lawlor, Murdo Black
Принадлежит: Axis Shield Diagnostics Ltd

A molecule which recognises holo-DBP but which does not recognise apo-DBP or has relatively low affinity thereto.

Подробнее
Номер записи: 53
15-03-2012 дата публикации

Dual targeting antibody of novel form, and use thereof

Номер: US20120065380A1
Автор: Jin San Yoo, Sang Ryeol Shim, Sung Woo Kim, Weon Sup Lee
Принадлежит: Pharmabcine Inc

The present invention relates to: a dual targeting antibody of a novel form having a water-soluble ligand fused to the N-terminus of a heavy chain or light chain of an antibody; a DNA encoding the dual targeting antibody; a recombinant expression vector containing the DNA; a host cell which is transformed with the recombinant expression vector; a method for preparing the dual targeting antibody by culturing the host cell; and a pharmaceutical composition including the dual targeting antibody.

Подробнее
Номер записи: 54
15-03-2012 дата публикации

Test agent for visceral obesity and use thereof

Номер: US20120066777A1
Автор: Atsunori Kashiwagi, Hiroshi Maegawa, Masatomo Rokushima, Minoru Ikeda, Minoru Suzuki, Shiro Maeda, Tatsuya Takahashi, Tohru Tani, Yoshihiro Kawamura
Принадлежит: RIKEN Institute of Physical and Chemical Research, Shiga University of Medical Science NUC, Shionogi and Co Ltd

Disclosed are: a method for detecting (diagnosing) visceral obesity in a subject; a test agent useful for the method; a method for searching for a substance that can be used as an active ingredient for ameliorating visceral obesity; and an ameliorating agent for visceral obesity or a medicinal agent for preventing a metabolic disease developed as a result of the progression of visceral obesity. As the test agent, a polynucleotide which comprises at least 15 nucleotides and can hybridize with a nucleotide sequence for coiled-coil domain containing protein 3 (CCDC3) gene or a nucleotide sequence complementary to the nucleotide sequence under stringent conditions or an antibody capable of recognizing CCDC3 protein is used.

Подробнее
Номер записи: 55
22-03-2012 дата публикации

Treatment of vascularized pigment epithelial detachment with anti-vegf therapy

Номер: US20120070428A1
Автор: Clement K. Chan, Prema Abraham
Принадлежит: Genentech Inc

Methods for treating vascularized pigment epithelial detachment using anti-VEGF agents are disclosed.

Подробнее
Номер записи: 56
22-03-2012 дата публикации

Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof

Номер: US20120070429A1
Автор: Leslie S. Johnson, Ling Huang
Принадлежит: Macrogenics Inc

The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

Подробнее
Номер записи: 57
22-03-2012 дата публикации

Methods of treating inflammation

Номер: US20120070449A1
Автор: Einat Toister, Idit Shachar
Принадлежит: Yeda Research and Development Co Ltd

A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation.

Подробнее
Номер записи: 58
22-03-2012 дата публикации

Lenalidomide and Thalidomide Immunoassays

Номер: US20120071632A1
Автор: Alexander Volkov, Howard Sard, Jodi Blake Courtney, Salvatore J. Salamone, Vishnumurthy Hegde
Принадлежит: Individual

Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Подробнее
Номер записи: 59
22-03-2012 дата публикации

Prevention and treatment of blood coagulation-related disases

Номер: US20120073002A1
Автор: Hiroyuki Saito, Kazutaka Yoshihashi, Kunihiro Hattori, Takehisa Kitazawa
Принадлежит: Chugai Pharmaceutical Co Ltd

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

Подробнее
Номер записи: 60
29-03-2012 дата публикации

Antagonists of pcsk9

Номер: US20120076799A1
Автор: Ayesha Sitlani, Carl P. Sparrow, Holly A. Hammond, Jon H. Condra, Shilpa Pandit
Принадлежит: Merck Sharp and Dohme LLC

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Подробнее
Номер записи: 61
29-03-2012 дата публикации

Human cytomegalovirus neutralising antibodies and use thereof

Номер: US20120076801A1
Автор: Annalisa Macagno, Antonio Lanzavecchia
Принадлежит: Humabs Llc

The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.

Подробнее
Номер записи: 62
29-03-2012 дата публикации

Antibodies to troponin i and methods of use thereof

Номер: US20120076803A1
Автор: Bailin Tu, Dagang Huang, Joan D. Tyner, Lowell J. Tyner, Robert N. Ziemann, Susan E. Brophy
Принадлежит: ABBOTT LABORATORIES

The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.

Подробнее
Номер записи: 63
29-03-2012 дата публикации

Use of Toll-like receptor-9 agonists, Toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of Toll-like receptor-4-associated disorders

Номер: US20120077868A1
Автор: David J. Hackam
Принадлежит: Individual

The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.

Подробнее
Номер записи: 64
29-03-2012 дата публикации

Method for removing viruses from high concentration monoclonal antibody solution

Номер: US20120077963A1
Автор: Masayasu Komuro, Tomoko Hongo
Принадлежит: Asahi Kasei Medical Co Ltd

An object of the present invention is to provide a method for removing even small viruses from a high concentration monoclonal antibody solution using a membrane, and thus for recovering the antibody within a short time at high yield in the form of a filtrate. The present invention provides a method for producing a preparation containing a monoclonal antibody, which comprises a step of removing viruses by filtering viruses in a monoclonal antibody solution using a virus-removing membrane, wherein (1) the monomer content of the monoclonal antibody accounts for 90% or more; (2) the monoclonal antibody concentration in the monoclonal antibody solution ranges from 20 mg/ml to 100 mg/ml; (3) the monoclonal antibody solution contains at least a basic amino acid; and (4) the parvovirus removal rate of the virus-removing membrane satisfies the following conditions: LRV (Log Reduction Value: logarithmic reduction value) ≧4.

Подробнее
Номер записи: 65
29-03-2012 дата публикации

Antagonists of pcsk9

Номер: US20120077964A1
Автор: Ayesha Sitlani, Carl P. Sparrow, Holly A. Hammond, Jon H. Condra, Shilpa Pandit
Принадлежит: Merck Sharp and Dohme LLC

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Подробнее
Номер записи: 66
05-04-2012 дата публикации

Soluble il-17ra/rc fusion proteins and related methods

Номер: US20120082668A1
Автор: Gao Zeren, Mark W. Rixon, Steven D. Levin
Принадлежит: Zymogenetics Inc

Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.

Подробнее
Номер записи: 67
05-04-2012 дата публикации

Cd33 binding agents

Номер: US20120082670A1
Автор: Eric Borges, Karl-Heinz Heider, Paul Adam, Renate Konopitzky
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to CD33 binding agents for use in such therapies, e.g. in the treatment of myeloid cell malignancies and myelodysplastic syndrome (MDS).

Подробнее
Номер записи: 68
05-04-2012 дата публикации

Methods for preventing and treating angioedema

Номер: US20120082676A1
Автор: Berhane Ghebrehiwet
Принадлежит: Research Foundation of State University of New York

One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R.

Подробнее
Номер записи: 69
05-04-2012 дата публикации

Antagonists of pcsk9

Номер: US20120082680A1
Автор: Ayesha Sitlani, Carl P. Sparrow, Dana D. Wood, Jon H. Condra, Shilpa Pandit, Timothy S. Fisher
Принадлежит: Merck Sharp and Dohme LLC

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Подробнее
Номер записи: 70
05-04-2012 дата публикации

Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

Номер: US20120082681A1
Автор: Andrea Polzer, Christoph Heusser, Christoph Schwaerzler, Gabriela Wochnik-Veltrup, Ingo Klagge, José M. Carballido Herrera, Stefan Hartle
Принадлежит: NOVARTIS AG

The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Подробнее
Номер записи: 71
05-04-2012 дата публикации

Myostatin binding agents

Номер: US20120083442A1
Автор: Hosung Min, Hq Han, Thomas Charles Boone
Принадлежит: AMGEN INC

The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

Подробнее
Номер записи: 72
12-04-2012 дата публикации

Novel caviidae allergens and uses thereof

Номер: US20120087870A1
Автор: Christiane Hilger, François Hentges
Принадлежит: Individual

The present invention relates to the provision of a nucleic acid molecule encoding a Caviidae allergen comprising a polynucleotide selected from the group consisting of (a) a polynucleotide sequence as shown in SEQ ID NO 1 (Cav p 3), SEQ ID NO 5 (Cav p 2), SEQ ID NO 3 (Cav p 6) or SEQ ID NO 19 ( Cavia porcellus allergen 1 a) or a fragment thereof, (b) a polynucleotide sequence encoding a polypeptide as shown in SEQ ID NO 2 (Cav p 3), SEQ ID NO 6 (Cav p 2), SEQ ID NO 4 (Cav p 6) or SEQ ID NO 20 ( Cavia porcellus allergen 1 a) or a fragment thereof (c) a polynucleotide sequence which has at least 80% identity to the polynucleotides as defined in (a) or (b) encoding a Caviidae allergen or a fragment thereof, (d) a polynucleotide sequence encoding a polypeptide which has at least 85% identity to the polypeptide as shown in SEQ ID NO 2 (Cav p 3), SEQ ID NO 6 (Cav p 2), SEQ ID NO 4 (Cav p 6) or SEQ ID NO 20 ( Cavia porcellus allergen 1 a ) or a fragment thereof, (e) a polynucleotide sequence which hybridizes to the polynucleotide sequence of any one of (a) to (d) and whereby the coding strand encodes a Caviidae allergen or a fragment thereof, (f) a polynucleotide sequence encoding a polypeptide as encoded by the nucleotide sequence of any one of (a) to (e) wherein at least one amino acid is deleted, substituted inserted or added and whereby said polynucleotide encodes a Caviidae allergen or a fragment thereof, and (g) a polynucleotide sequence being degenerate as a result of the generic code to the polynucleotide sequence as defined in any one of (a) to (f) The present invention also provides for a method for producing the polypeptides (Cav p3, Cav p6, Cavia porcellus allergen 1 a) encoded by said polynucleotides Moreover, the use of such allergens in a medical setting (e g in form of a pharmaceutical and/or diagnostic composition) an in vitro method for determining the allergenicity to Caviidae as well as an method for identifying potential antagonists or agonists of the ...

Подробнее
Номер записи: 73
12-04-2012 дата публикации

Therapeutics for age-related macular degeneration

Номер: US20120087928A1
Автор: Kameran Lashkari
Принадлежит: Individual

The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.

Подробнее
Номер записи: 74
12-04-2012 дата публикации

Therapeutic and diagnostic anti-hsp70 antibodies

Номер: US20120087931A1
Автор: Gabriele Multhoff
Принадлежит: Multimmune GmbH

Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue and cells, in particular on tumor cells and infected cells.

Подробнее
Номер записи: 75
19-04-2012 дата публикации

Anti-vegf-d antibodies

Номер: US20120093811A1
Автор: Andrew J. Pow, George Kopsidas, Irene Koukoulas, Jason W. Simmonds, Vincent Emil W. Batori
Принадлежит: Vegenics Pty Ltd

The invention relates to an isolated antibody that specifically binds vascular endothelial growth factor-D (VEGF-D) and to a humanized antibody that specifically binds VEGF-D.

Подробнее
Номер записи: 76
19-04-2012 дата публикации

Non-lipidated variants of neisseria meningitidis orf2086 antigens

Номер: US20120093852A1
Автор: Annaliesa Sybil Anderson, Justin Keith Moran, Kathrin Ute Jansen, Mark E. Ruppen, Susan Kay Hoiseth
Принадлежит: WYETH LLC

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis , and methods related thereto.

Подробнее
Номер записи: 77
19-04-2012 дата публикации

Nucleotide repeat expansion-associated polypeptides and uses thereof

Номер: US20120094299A1
Автор: Laura P.W. Ranum, Tao Zu
Принадлежит: University of Minnesota

Isolated polypeptides that are endogenously expressed from nucleotide repeat expansions are disclosed. In some cases, the polypeptides include polypeptide repeats. In some cases, the polypeptide repeats include at least five contiguous repeats of a single amino acid. In other cases, the repeats include at least six contiguous amino acids of a tetra- or penta-amino acid repeat block.

Подробнее
Номер записи: 78
19-04-2012 дата публикации

Mice That Make VL Binding Proteins

Номер: US20120096572A1
Автор: Andrew J. Murphy, Cagan Gurer, Karolina A. Hosiawa, Lynn Macdonald, Sean Stevens
Принадлежит: Regeneron Pharmaceuticals Inc

Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.

Подробнее
Номер записи: 79
26-04-2012 дата публикации

Humanized antibodies against light and uses thereof

Номер: US20120100074A1
Автор: Bridget A. Cooksey, Craig Rosen, Palanisamy Kanakaraj, Rodger Smith, Viktor Roschke
Принадлежит: Teva Biopharmaceuticals USA Inc

The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).

Подробнее
Номер записи: 80
26-04-2012 дата публикации

Use of anti-cd20 antibody for treating primary intraocular lymphoma

Номер: US20120100133A1
Автор: Catherine Fridman, Remi Urbain, Sylvain Fisson
Принадлежит: LFB Biotechnologies SAS

An embodiment relates to a monoclonal antibody directed against the CD20 antgen, in which the variable region of each of the light chains is coded by murine nucleic acid sequence SEQ ID NO:1, the variable region of each of the heavy chains is coded by murine nucleic acid sequence SEQ ID NO: 2, and the constant regions of the light chains and of the heavy chains originate from a non-murine species, said antibody being used for treating primary intraocular lymphoma.

Подробнее
Номер записи: 81
26-04-2012 дата публикации

CD86 Antagonist Multi-Target Binding Proteins

Номер: US20120100139A1
Автор: John W. Blankenship, Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, Sateesh Kumar Natarajan
Принадлежит: Emergent Product Development Seattle LLC

This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Подробнее
Номер записи: 82
26-04-2012 дата публикации

Anti-ferroportin 1 monoclonal antibodies and uses thereof

Номер: US20120100148A9
Автор: Derrick Ryan Witcher, Donmienne Doen Mun Leung, Joseph Vincent Manetta, Peng Luan, Ying Tang
Принадлежит: Eli Lilly and Co

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.

Подробнее
Номер записи: 83
26-04-2012 дата публикации

Anti-human cd52 immunoglobulins

Номер: US20120100152A1
Автор: Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
Принадлежит: Genzyme Corp

The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.

Подробнее
Номер записи: 84
26-04-2012 дата публикации

Antibodies having altered effector function and methods for making the same

Номер: US20120100575A1
Автор: Ellen Garber, Frederick R. Taylor
Принадлежит: BIOGEN IDEC MA INC

The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.

Подробнее
Номер записи: 85
26-04-2012 дата публикации

Inhibition of secretion from non-neuronal cells

Номер: US20120101027A1
Автор: Conrad Padraig Quinn, John Andrew Chaddock, John Robert Purkiss, Keith Alan Foster
Принадлежит: Syntaxin Ltd

The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.

Подробнее
Номер записи: 86
26-04-2012 дата публикации

Compositions and methods for biological remodeling with frozen particle compositions

Номер: US20120101738A1
Автор: Daniel B. Cook, Edward S. Boyden, Elizabeth A. Sweeney, Eric C. Leuthardt, Lowell L. Wood, JR., Nathan P. Myhrvold, Roderick A. Hyde
Принадлежит: SEARETE LLC

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Подробнее
Номер записи: 87
03-05-2012 дата публикации

Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof

Номер: US20120108492A1
Автор: James Kovacs, Jonathan P. Hannan, V. Michael Holers
Принадлежит: University of Colorado

The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand's binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof.

Подробнее
Номер записи: 88
03-05-2012 дата публикации

Recombinant il-9 antibodies and uses thereof

Номер: US20120109097A1
Автор: Herren Wu, Jeffry D. Watkins, Jennifer Lynne Reed, Julian Davies, Ying Tang
Принадлежит: MEDIMMUNE LLC

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Подробнее
Номер записи: 89
10-05-2012 дата публикации

Method for treating immune disorders

Номер: US20120114555A1
Автор: Andrew T. Hutchinson, Darren R. Jones, Parisa Asvadi, Robert L. Raison, Rosanne D. Dunn
Принадлежит: IMMUNE SYSTEM THERAPEUTICS LTD

The present invention relates to the treatment of B-cell mediated immune disorders such as rheumatoid arthritis, systemic lupus erythromatomus, diabetes mellitus, and multiple sclerosis. In particular, the present invention relates to the treatment of B-cell mediated immune disorders using antibodies which bind to membrane-bound free light chain expressed on the surface of plasma cell precursors.

Подробнее
Номер записи: 90
10-05-2012 дата публикации

Methods for inhibiting cutaneous inflammation and hyperpigmentation

Номер: US20120114575A1
Автор: B. Jack Longley
Принадлежит: Columbia University of New York

This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treating contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.

Подробнее
Номер записи: 91
10-05-2012 дата публикации

Tslp promotes immune evasion and persistence of viruses

Номер: US20120114596A1
Автор: Bernhard Homey, Isabel Fernandez, Vassili Soumelis
Принадлежит: HEINRICH-HEINE-UNIVERSITAET, INSTITUT CURIE, Institut National de la Sante et de la Recherche Medicale INSERM

It relates to the treatment or prevention of a chronic viral infection with a Thymic Stromal Lymphopoietin (TSLP) antagonist thereby avoiding immune evasion and persistence of the virus. It also provides a method of prognosing the evolution of a cervical dysplasia by TSLP expression in a sample of said cervical dysplasia.

Подробнее
Номер записи: 92
10-05-2012 дата публикации

Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: ifn- ligands engage a novel receptor ifn-rn (crf2-12) and il-10r2 (crf2-4) for signaling andinduction of biological activities

Номер: US20120114603A1
Автор: Grant F. Gallagher, Sergei Kotenko
Принадлежит: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

Подробнее
Номер записи: 93
10-05-2012 дата публикации

Compositions and methods for inhibiting viral and/or bacterial infections

Номер: US20120114639A1
Автор: Michelle Adair Ozbun, Zurab Surviladze
Принадлежит: STC UNM

We describe herein compositions and methods related to inferring with microbial infection. Generally, the compositions include an infection antagonist that inhibits formation of a heparin sulfonated proteoglycan (HSPG)-containing infection complex. Generally, the methods include administering to a subject an amount of a composition as described herein effective to inhibit infection by a microorganism that that infects a host through interactions that involve HSPG.

Подробнее
Номер записи: 94
10-05-2012 дата публикации

Single chain antibodies against beta-amyloid peptide

Номер: US20120114650A1
Автор: Beka Solomon, Rachel Cohen-Kupiec
Принадлежит: Ramot at Tel Aviv University Ltd

Anti-AβP scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Aβp 1-40 and disaggregate Aβp 1-40 fibrils generated in vitro. The anti-Aβp scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-AβP scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.

Подробнее
Номер записи: 95
10-05-2012 дата публикации

Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa

Номер: US20120114657A1
Автор: Holger Koch, Michael Rudolf, Stefanie Fas
Принадлежит: Kenta Biotech AG

The present invention relates to a human monoclonal antibody specific for the serotype IATS 01 of P. aeruginosa , and a hybridoma producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.

Подробнее
Номер записи: 96
10-05-2012 дата публикации

Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Номер: US20120114671A1
Автор: Joan Seoane Suarez, José BASELGA TORRES, Silvia Penuelas Prieto
Принадлежит: Fundacio Hospital Universitari Vall dHebron Institut de Recerca FIR VHIR, Institucio Catalana de Recerca i Estudis Avancats ICREA

The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.

Подробнее
Номер записи: 97
10-05-2012 дата публикации

Integrin heterodimer and an alpha subunit thereof

Номер: US20120114708A1
Автор: Donald Gullberg
Принадлежит: HANSA MEDICAL AB

A recombinant or isolated integrin heterodimer comprising a novel subunit α11 in association with a subunit β is described. The integrin or the subunit α11 can be used as marker or target of all types of cells. The integrin or subunit α11 thereof can be used as marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.

Подробнее
Номер записи: 98
10-05-2012 дата публикации

Hydroxycholesterol immunoassay

Номер: US20120115169A1
Автор: James J. Donegan, Jeffrey Kroll Adams, Michael C. Mullenix, Robert Elliot Zipkin, Wayne Forrest Patton
Принадлежит: Enzo Life Sciences Inc

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.

Подробнее
Номер записи: 99
10-05-2012 дата публикации

Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same

Номер: US20120115221A1
Автор: Shuichi Nakatsuru, Yasuharu Nishimura, Yoshiaki Ikuta
Принадлежит: ONCOTHERAPY SCIENCE INC

It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.

Подробнее
Номер записи: 100